[G] = treated for gastrointestinal tumor; [R] = treated for renal cell carcinoma; [P] treated for pancreatic neuroendocrine tumor
- TRADE NAME: Sutent (Pfizer)
- INDICATIONS: Gastrointestinal stromal tumor, advanced renal cell carcinoma, advanced pancreatic neuroendocrine tumor
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), RET (Rearranged during Transfection) kinase inhibitor, Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 40–60 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Bevacizumab, Carbamazepine, Clarithromycin, Clozapine, Dexamethasone, Digoxin, Efavirenz, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Temsirolimus, Voriconazole
HEPATOTOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sunitinib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/25/2025
